Related references
Note: Only part of the references are listed.PTEN status in advanced colorectal cancer treated with cetuximab
F. V. Negri et al.
BRITISH JOURNAL OF CANCER (2010)
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
Geraldine Perkins et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
Mario Scartozzi et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
KRAS Mutation Testing in Colorectal Cancer
Thomas P. Plesec et al.
ADVANCES IN ANATOMIC PATHOLOGY (2009)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
The signal pathways in azoxymethane-induced colon cancer and preventive implications
Jiezhong Chen et al.
CANCER BIOLOGY & THERAPY (2009)
Role of Src family kinases in acquired resistance to EGFR therapies in cancer
Julie L. Boerner
CANCER BIOLOGY & THERAPY (2009)
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab
Deric L. Wheeler et al.
CANCER BIOLOGY & THERAPY (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
J. Veeken et al.
CURRENT CANCER DRUG TARGETS (2009)
Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines
Takashi Yamatodani et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Insulin-Insulin-Like Growth Factor Axis and Colon Cancer
Srikala S. Sridhar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Obesity, the PI3K/Akt signal pathway and colon cancer
X-F. Huang et al.
OBESITY REVIEWS (2009)
Nuclear EGFR contributes to acquired resistance to cetuximab
C. Li et al.
ONCOGENE (2009)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition
T. Fujisawa et al.
GUT (2008)
Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in ApcMin/+ colon epithelial cells
Jenifer I. Fenton et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer
Quanri Jin et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Next-generation DNA sequencing
Jay Shendure et al.
NATURE BIOTECHNOLOGY (2008)
Is Src the key to understanding metastasis and developing new treatments for colon cancer?
Jiezhong Chen
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2008)
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2008)
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
NATURE REVIEWS CANCER (2008)
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the Anti-EGFR monoclonal antibody cetuximab
Yang Lu et al.
CANCER RESEARCH (2007)
Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers
J. Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis
Yun Gao et al.
CANCER RESEARCH (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
M Taron et al.
CLINICAL CANCER RESEARCH (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Drug therapy - Systemic therapy for colorectal cancer
JA Meyerhardt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms
EE Calle et al.
NATURE REVIEWS CANCER (2004)
Epidermal growth factor receptor: mechanisms of activation and signalling
RN Jorissen et al.
EXPERIMENTAL CELL RESEARCH (2003)
EGFR blockade with ZD1839 (Iressa) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma
B Solomon et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Share Paper
